Pacific Biosciences of California, Inc. filings document operating results, governance changes, material agreements, and asset-disposition activity tied to its sequencing business. Recent Form 8-K reports furnish quarterly and full-year financial results, business updates, revenue categories for instruments, consumables, and services, and disclosures related to the company’s long-read sequencing focus.
The filing record also includes proxy materials covering board structure, director elections, executive compensation, equity awards, and stockholder voting matters. Other 8-K disclosures address board appointments, changes in accounting-officer responsibilities, operating responsibility assignments, intellectual-property arrangements, and the completed sale of assets related to short-read DNA sequencing technology.
Pacific Biosciences of California, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on June 3, 2026, at 9:00 a.m. Pacific Time. Stockholders of record at 5:00 p.m. Pacific Time on April 6, 2026, may attend and vote.
Stockholders will vote on electing six directors for one-year terms as part of the Board’s declassification process, ratifying Ernst & Young LLP as independent auditor for 2026, approving on an advisory basis 2025 executive compensation, and approving an amendment to the 2020 Equity Incentive Plan to add 16,000,000 shares to the share reserve. The proxy also outlines board structure, committee responsibilities, director independence, board diversity, director pay (cash retainers and equity awards), and the company’s cybersecurity and responsible business oversight framework.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. director Christopher Gibson reported equity awards consisting of stock options and restricted stock units tied to his recent Board appointment. He received stock options covering 77,842 shares of Common Stock at an exercise price of $1.52 per share, expiring on April 8, 2036. One-third of these option shares will vest on March 3, 2027, with the remainder vesting in equal monthly installments over the following 24 months, contingent on continued Board service. He also acquired 57,473 shares of Common Stock represented by restricted stock units that vest in three equal annual installments on March 3 of 2027, 2028, and 2029, subject to his continued service as a director. Following these grants, he directly holds 111,386 shares of Common Stock.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer James R. Gibson II reported an open-market sale of 88,185 shares of common stock at a weighted average price of $1.37 per share. According to the filing, these shares were mandatorily sold to cover tax withholding obligations tied to vesting restricted stock units, and he continues to hold 1,245,663 shares directly.
Pacific Biosciences of California Inc: The Vanguard Group filed Amendment No. 4 to a Schedule 13G/A reporting 0 shares beneficially owned (0%) as of 03/13/2026. The filing notes an internal realignment effective January 12, 2026 that led certain Vanguard subsidiaries to report separately.
Pacific Biosciences of California, Inc. disclosed two developments. First, Chief Accounting Officer Michele Farmer will voluntarily resign effective March 21, 2026, to pursue another opportunity. The company states her departure is not related to any disagreement over operations or accounting, and she will not receive severance. Chief Financial Officer Jim R. Gibson will also serve as principal accounting officer, with no change to his compensation.
Second, on March 5, 2026, the company signed a binding term sheet with Personal Genomics of Taiwan, Inc. It provides a worldwide, royalty-free, non-exclusive license to U.S. Patent No. 7,767,441 and related patents, plus a five-and-a-half-year covenant not to sue under PGI patents, and dismissal of all litigation between the parties. Pacific Biosciences will make fixed payments of $8,000,000 in the first quarter of 2026 and $5,000,000 in the first quarter of each of 2027, 2028 and 2029, with the 2027 payment increasing by $1,000,000 if 2026 revenue reaches $165,000,000 and by another $1,000,000 if it reaches $180,000,000.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. director Christopher Gibson reported equity awards connected to his election to the Board. On March 3, 2026, he received stock options for 73,087 shares at an exercise price of $0.00 and a grant of 53,913 shares of common stock represented by restricted stock units.
The RSUs vest in three equal annual installments on March 3, 2027, 2028, and 2029, conditioned on continued Board service. One‑third of the stock options vest on March 3, 2027, with the remaining options vesting in equal monthly installments over the following 24 months while he remains a director.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. filed an initial ownership report for Christopher Gibson on Form 3. The filing identifies Gibson as a director of the company and does not list any buy, sell, or other share transactions. It simply establishes his status as an insider for future reporting.
Pacific Biosciences of California, Inc. appointed Christopher Gibson, Ph.D., to its Board of Directors as a Class I director effective March 3, 2026, expanding the board to ten members. His initial term runs until the 2026 annual meeting, and he will also serve on the Science and Technology Committee.
Dr. Gibson co-founded and chairs Recursion, a clinical-stage biotechnology company known for its AI-driven drug discovery platform that combines large-scale biological data with machine learning. PacBio highlights his background in integrating automation, high‑dimensional biology and artificial intelligence as directly relevant to its strategy of pairing HiFi long-read sequencing with advanced analytics.
The company states there are no related-party transactions or family relationships involving Dr. Gibson that require disclosure, and he will receive compensation under PacBio’s standard non‑employee director policy along with the company’s standard indemnification agreement. A press release dated March 5, 2026, further describes his appointment and PacBio’s view that AI-enabled data tools are increasingly important as sequencing datasets grow.